Key Takeaways
- Strong quarter, broad-based beat: US revenue hit an all-time high of $222 mn, up 43% YoY, while India branded prescriptions continued to outgrow the market and South Africa became the #2 player by prescription share.
- Gross margin expanded 230 bps YoY to 64.7%, driven by new launch contributions and a favorable product mix shift, reinforcing confidence in the full-year EBITDA trending toward 23%.
- The US story is a structural rebalancing, not a one-off: A combination of competitor exits, supply chain localization, and channel-specific buying programs is lifting the base business, with management comfortable guiding to a $210–215 mn quarterly run-rate.
- The complex generics pipeline is being actively derisked: Generic Advair is moving to an in-house site, Abraxane to a CMO, and three differentiated products are in clinical trials, with filings targeted in FY24 and FY25.
- What to watch next quarter: Whether the US base business holds at the guided run-rate, any update on the Goa facility re-inspection, and the pace of peptide approvals.
US Business: The Structural Shift
- Record quarter, multiple drivers: The US delivered its highest-ever sales at $222 mn, growing 43% YoY. The beat came from a combination of factors: Lanreotide market share improved to 18%, Albuterol share stabilized after a Q4 dip, and the non-Revlimid base portfolio gained significantly.
- Supply chain rebalancing is a tailwind: US companies amalgamating, merging, or going bankrupt are eliminating competitors. Certain channels now only buy domestically manufactured products, creating a structural advantage for Cipla's existing families. Management flagged this as a multi-quarter dynamic, not a transient spike.
- Albuterol stabilized, recall provided for: The Q4 FY23 share drop has reversed and the franchise has stabilized. A recall on certain batches was fully provided for in Q1, and management expressed confidence in the remaining batches after analysis.
- Revlimid performed to expectations, but volume share is negligible: Management declined to disclose volume share, calling it "not the right metric to track on this launch" given the product's dynamics.
- Base business run-rate guided: Management is comfortable with a USD 210–215 mn quarterly trajectory going forward, with a commitment to flag any fall-off in the base.
Vohra: "A large number of US companies are either amalgamating, merging, or are going bankrupt. That is eliminating certain number of people in the system. It's also having an impact on certain channels in the US, which only buy products which are made domestically. So we are seeing a rebalancing of the supply chain happening, because of which, our base families are actually growing."
India Business: Market-Beating Growth
- Branded prescriptions outpaced IPM growth with sustained momentum across all therapies. Chronic share in revenue moved from 58% to 60% YoY, and industry market share improved from 8.4% to 8.6%.
- Foracort grew 27% in Q1, making it one of the fastest-growing brands in the top 10 IPM brands, driven by a strategy of making big brands bigger. Ibugesic Plus became the 11th Cipla brand in the top 100 IPM brands.
- Trade generics maintained market leadership, supported by traction in big brands and the addition of 23 new products to build the future portfolio.
- One-India franchise grew 12%, with the impact of NLEM pricing largely offset by multiple measures. New launches, including in-licensed products Galvus and Scapho, contributed to growth.
- Rep additions pay back fast: Cipla added 250–300 reps in Q1 and will reach 500 net additions by Q2 before pausing. Management stated each rep pays back within 6–9 months, and the mix shift toward chronic therapies further supports profitability.
- Consumer health delivered strong double-digit growth with margins nearing mid-teens, leveraging brand strength and attractive packaging. Management is excited about the categories (pain, rehydration, cold/flu/cough) and aims for a well-diversified portfolio.
Vohra: "We are very excited about that business because that's a business which we realize that more people want to stay well longer than they are sick."
Complex Pipeline & Facility Derisking
- Three differentiated products are undergoing clinical trials with filings targeted in FY24 and FY25. Symbicort is expected to be filed by the end of this year.
- Generic Advair is being derisked to an in-house facility, with the product expected to reach market in 12 months. Management expects no incremental generic competition in that timeframe.
- Generic Abraxane is being derisked to a CMO site, with the ability to supply from both sites expected by FY25. The market remains supply-constrained, with no player getting enough product.
- Peptide pipeline is site-independent: Four to five peptide launches are expected in the next two years, with a couple of new peptides to be filed in the same period. These are entirely third-party manufactured, with no dependence on Goa or Indore; only approvals are pending.
- Goa re-inspection is hoped for in the second half of this financial year, though no timeline is confirmed. The Pfizer facility situation is being monitored, but Cipla has received no official intimation of shortages for any overlapping products.
Vohra: "Beyond this year if Indore is not cleared, yes, but not beyond FY '25."
South Africa & International Markets
- South Africa became the #2 player in the prescription market by market share, with a four-year CAGR of 8.6% in a market growing at 3.6%. The private market grew 13% YoY, powered by focused therapies in the prescription business and 16% growth in the OTC portfolio.
- Management aims to inch toward the #1 position in South Africa over the next few years, supported by small inorganic opportunities. The business gets tremendous operating leverage from top-line growth.
- International markets will focus on driving growth in select geographies, with sustained performance expected from the South Africa franchise across private market, select tenders, and improving margins.
Margins & Investment
- Gross margin expanded 230 bps YoY to 64.7%, driven by contributions from new launches and an overall mix change toward higher-value products.
- R&D investment rose 27% YoY, driven by ongoing clinical trials on the differentiated portfolio and other developmental efforts.
- Full-year EBITDA is expected to trend toward 23%, with confidence underpinned by all markets: the US and India are larger businesses, while South Africa gets leverage from top-line growth.
- Capex guidance is 4–5% of revenue, or INR 1,000–1,500 crore per annum, split roughly 50-50 between maintenance and growth. Management declined to give a more specific split.
- Inorganic deployment will continue within hurdle rates: in India for branded opportunities, in South Africa for small acquisitions to reach #1, and in the US for white space in core strengths like respiratory.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US base business run-rate | USD 210–215 mn per quarter; will flag any fall-off | Ongoing, quarter-by-quarter |
| Full-year EBITDA margin | Trending toward 23% | FY24 |
| Generic Advair launch | Product to market with no incremental generic competition expected | Within 12 months |
| Generic Abraxane dual-site supply | Ability to supply from both current and CMO sites | By FY25 |
| Symbicort filing | Filed with USFDA | By end of CY23 |
| Peptide launches | 4–5 launches; a couple of new peptides filed | Next two years |
| India rep additions | 500 net additions, then pause | By Q2 FY24 |
| Capex | 4–5% of revenue, INR 1,000–1,500 crore p.a. | Annual |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue | ₹6,329 cr, +18% YoY |
| EBITDA margin | 23.6% (reported, excluding other income), includes higher R&D and provisions |
| Gross margin | 64.7%, +230 bps YoY, driven by new launches and mix change |
| Profit after tax | ₹996 cr, 15.7% of sales |
| Effective tax rate | 27.5%, constant YoY |
| R&D investment | ₹349 cr, 5.5% of revenue, +27% YoY |
| Total expenses | ₹2,598 cr, +3.8% QoQ |
| Net cash position | ₹6,138 cr, improved from ₹5,469 cr in March |
| Full-year EBITDA guidance | ~23%, raised from 22% |
| US business revenue | $222 mn (USD22.2 cr), +43% YoY, highest ever |
| US base business quarterly run-rate | $210–215 mn (USD21–21.5 cr), up from $190–200 mn last quarter |
| India branded prescriptions growth | Significantly higher than IPM growth (MAT June '23) |
| India chronic therapies revenue share | 60%, up from 58% YoY; industry market share improved from 8.4% to 8.6% |
| Foracort growth | 27% YoY, one of the fastest in top 10 IPM brands |
| South Africa private market growth | 13% YoY in local currency; OTC portfolio grew 16% |
| South Africa market position | Second largest player in prescription market by market share |
| Lanreotide US market share | 18% as per MAT May '23 |
| India MR net additions | 250–300 added in Q1; targeting 500 net additions by Q2 |
| Consumer health revenue | ~₹385 cr, roughly 14% of total revenue |
| Capex guidance | 4–5% of revenue, ₹1,000–1,500 cr per annum, roughly 50-50 maintenance vs growth |